Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
British Journal of Cancer
|
June 16, 2011
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
J Cassidy, S Clarke, E Díaz-Rubio, et al.
Gynecologic Oncology
|
November 5, 1997
Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies
I Cohen, Y Beyth, M M Altaras, et al.
European Journal of Human Genetics : EJHG
|
August 10, 1999
Common origin of the I1307K APC polymorphism in Ashkenazi and non-Ashkenazi Jews
Y Patael, A Figer, R Gershoni-Baruch, et al.
Cancer
|
November 1, 1987
Familial colon cancer in the Tel-Aviv area and the influence of ethnic origin
P Rozen, H T Lynch, A Figer, et al.
Genetic Testing
|
September 12, 2001
The I1307K APC polymorphism: prevalence in non-Ashkenazi Jews and evidence for a founder effect
R Shtoyerman-Chen, E Friedman, A Figer, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists
|
April 1, 1996
Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients
I Cohen, M M Altaras, J Shapira, et al.
Genetic Testing
|
January 6, 2001
Genetic analyses of male breast cancer in Israel
R S Sverdlov, I Barshack, R B Bar Sade, et al.
British Journal of Cancer
|
November 27, 2001
Phenotypic characteristics of colo-rectal cancer in I1307K APC germline mutation carriers compared with sporadic cases
A Figer, R Shtoyerman-Chen, A Tamir, et al.
Breast Cancer Research and Treatment
|
June 16, 1999
Dose-dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer patients
I Cohen, E Perel, R Tepper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2009
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study
F-C Bidard, C Tournigand, T André, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
British Journal of Cancer
|
June 16, 2011
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
J Cassidy, S Clarke, E Díaz-Rubio, et al.
Gynecologic Oncology
|
November 5, 1997
Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies
I Cohen, Y Beyth, M M Altaras, et al.
European Journal of Human Genetics : EJHG
|
August 10, 1999
Common origin of the I1307K APC polymorphism in Ashkenazi and non-Ashkenazi Jews
Y Patael, A Figer, R Gershoni-Baruch, et al.
Cancer
|
November 1, 1987
Familial colon cancer in the Tel-Aviv area and the influence of ethnic origin
P Rozen, H T Lynch, A Figer, et al.
Genetic Testing
|
September 12, 2001
The I1307K APC polymorphism: prevalence in non-Ashkenazi Jews and evidence for a founder effect
R Shtoyerman-Chen, E Friedman, A Figer, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists
|
April 1, 1996
Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients
I Cohen, M M Altaras, J Shapira, et al.
Genetic Testing
|
January 6, 2001
Genetic analyses of male breast cancer in Israel
R S Sverdlov, I Barshack, R B Bar Sade, et al.
British Journal of Cancer
|
November 27, 2001
Phenotypic characteristics of colo-rectal cancer in I1307K APC germline mutation carriers compared with sporadic cases
A Figer, R Shtoyerman-Chen, A Tamir, et al.
Breast Cancer Research and Treatment
|
June 16, 1999
Dose-dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer patients
I Cohen, E Perel, R Tepper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2009
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study
F-C Bidard, C Tournigand, T André, et al.
Page
of 5